Table 14.
Summary of findings table for treatment with erenumab 140 mg monthly subcutaneous injection compared with no treatment for prevention of chronic migraine
| Outcomes | Anticipated absolute effects*(95% CI) | Relative effect(95% CI) | № of participants (studies) | Certainty of the evidence(GRADE) | Comments | |
|---|---|---|---|---|---|---|
| Risk with placebo | Risk with erenumab | |||||
| Reduction of monthly migraine days follow up: 3 months | The mean reduction of monthly migraine days was − 4.2 days | The mean reduction of monthly migraine days in the intervention group was 2.5 days fewer (3.5 fewer to 1.4 fewer) | – | 468(1 RCT) | ⨁⨁⨁◯MEDIUMa | Treatment with Erenumab 140 mg reduces monthly migraine days slightly compared to placebo. |
| Reduction of monthly acute treatment days follow up: 3 months | The mean reduction of monthly acute treatment days was −1.6 days | The mean reduction of monthly acute treatment days in the intervention group was 2.6 days fewer (3.3 fewer to 1.8 fewer) | – | 468 (1 RCT) | ⨁⨁⨁◯MEDIUMa | Treatment with Erenumab 140 mg reduces monthly acute treatment days slightly compared to placebo. |
| At least 50% reduction of monthly migraine days follow up: 3 months | 235 per 1000 | 412 per 1000(314 to 540) | RR 1.7531(1.3359 to 2.3007) | 468(1 RCT) | ⨁⨁⨁◯MEDIUMa | Treatment with Erenumab 140 mg results in at least 50% reduction of monthly migraine days compared to placebo. |
| Serious adverse events follow up: 3 months | 25 per 1000 | 11 per 1000 (2 to 51) | RR 0.4286(0.0900 to 2.0408) | 470(1 RCT) | ⨁⨁⨁◯MEDIUMa | Treatment with Erenumab 140 mg results in a small unimportant decrease of serious adverse event occurrence compared to placebo. |
| Mortalityfollow up: 3 months | 0 per 1000 | 0 per 1000(0 to 0) | not estimable | 470(1 RCT) | No deaths were observed with treatment with Erenumab 140 mg or placebo | |
CI: Confidence interval; RR: Risk ratio; RCT: randomized controlled trial; aDowngraded once due to imprecision: phase II study
GRADE Working Group grades of evidenceHigh certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect